Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AZD 1390

Next Previous
Drug Profile

AZD 1390

Alternative Names: [11C]-AZD1390; AZD1390; Radiolabeled AZD-1390

Latest Information Update: 13 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; Global Coalition for Adaptive Research; Mayo Clinic
  • Class Antineoplastics; Radiosensitisers; Small molecules
  • Mechanism of Action Ataxia telangiectasia mutated protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Glioblastoma
  • Phase I Solid tumours
  • Preclinical Meningioma
  • No development reported Brain metastases; Breast cancer; Cancer; Non-small cell lung cancer; Soft tissue sarcoma

Most Recent Events

  • 08 Sep 2025 AstraZeneca plans a phase II/III trial for Glioblastoma in Germany (PO) (CTIS2025-521421-32-00)
  • 28 Aug 2025 No recent reports of development identified for phase-I development in Soft tissue sarcoma(First-line therapy, Neoadjuvant therapy) in Netherlands (PO)
  • 25 Jun 2025 3900166-KDM updated, Clinical- PD updated, HE added

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top